Robert Uger - 07 May 2021 Form 4 Insider Report for Trillium Therapeutics Inc.

Role: Chief Scientific Officer
Signature: /s/ James Parsons, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 07 May 2021
Net transactions value: -$32,767
Form type: 4
Filing time: 11 May 2021, 16:24:33 UTC
Next filing: 09 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRIL	Common Shares	Options Exercise	$1,141	+3,646		$0.3130^*	3,646	07 May 2021	Direct	F1, F2
transaction	TRIL	Common Shares	Sale	$33,908	-3,646	-100%	$9.30^*	0	07 May 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRIL	Stock Option (Right to Buy)	Options Exercise	$0	-3,646	-3.2%	$0.000000	109,375	07 May 2021	Common Shares	3,646	$0.3130	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8237 USD.
F3	25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.